Expression and clinical significance of cytokine cyclin 6(CDC6) in pancreatic ductal adenocarcinoma
10.3760/cma.j.cn121382-20220802-00506
- VernacularTitle:细胞分裂周期蛋白6（CDC6）在胰腺导管腺癌中的表达及临床意义
- Author:
Chunxiang XUE
1
;
Jing CHEN
Author Information
1. 天津康复疗养中心综合内科，天津 300381
- Keywords:
Cytokinesis cycle protein 6;
Pancreatic cancer;
Biomarker
- From:
International Journal of Biomedical Engineering
2022;45(5):409-413
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of cytokine cyclin 6 (CDC6) in pancreatic ductal adenocarcinoma, and its correlation with prognosis.Methods:The expression levels of CDC6 mRNA in pancreatic cancer tissues and normal tissues adjacent to the cancer were analyzed using the gene expression interaction analysis (GEPIA) database, and the correlation between CDC6 and the clinical prognosis of pancreatic cancer was analyzed using Kaplan-Meier. The clinicopathological characteristics of 80 patients with pancreatic ductal adenocarcinoma were retrospectively analyzed. The expression of CDC6 in pancreatic cancer tissues and normal tissues adjacent to the cancer was detected by immunohistochemical staining, and the data were analyzed by Graphpad 8.0 software to explore the clinical significance of high CDC6 protein expression.Results:Immunohistochemical staining results showed that the expression of CDC6 in pancreatic cancer tissues was much higher than that in normal tissues ( P<0.05), and the correlation between CDC6 and age, gender, and tumor grade of pancreatic cancer patients was not statistically significant (all P>0.05), but closely correlated with the size of the tumor ( P<0.05). Conclusions:CDC6 is closely related to the clinical prognosis of pancreatic cancer and is highly expressed in the developmental evolution of pancreatic cancer. Therefore, CDC6 is expected to be a target and potential biomarker for pancreatic cancer therapy.
